Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Cogent Biosciences (COGT) Amortization of Deferred Charges (2017 - 2026)

Cogent Biosciences' Amortization of Deferred Charges history spans 4 years, with the latest figure at $278000.0 for Q1 2026.

Quarterly Amortization of Deferred Charges changed N/A to $278000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $879000.0 through Mar 2026, up 4783.33% year-over-year, with the annual reading at $601000.0 for FY2025, N/A changed from the prior year.
Amortization of Deferred Charges came in at $278000.0 for Q1 2026, up from $238000.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $300000.0 in Q3 2025 to a low of $63000.0 in Q2 2025.